-

Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments Program received a Top Project award for achieving outstanding results in reducing waste. The award is sponsored by Environment+Energy Leader, a leading publisher of environmental, energy and sustainability best practices and research.

Agilent’s Certified Pre-Owned Instruments Program gives Agilent lab customers the option to trade in their used analytical instrument for cash or toward the purchase of a new instrument. Customers can also return select decommissioned instruments to Agilent for recycling.

Agilent refurbishes used systems to new instrument standards, then resells them to customers who might not otherwise have access to high-quality instruments due to budget constraints. Systems that cannot be refurbished to Agilent’s high standards are evaluated for part reuse and recycling wherever feasible.

In fiscal year 2021, Agilent bought back over 900 used instruments from customers; sold over 3,500 certified pre-owned instruments; and took back 2,000 instruments through the program.

The Certified Pre-Owned Instruments Program is a contributor to Agilent’s Environmental, Social and Governance (ESG) focus and complements other product sustainability initiatives within the company, including designing analytical instruments to use less energy and produce less waste; product labeling that indicates the environmental footprint of select Agilent instruments; leadership in lab sustainability practices; and digital technology like CrossLab Connect that enable labs to operate more efficiently through automation, artificial intelligence, and virtual support. The initiative also advances Agilent’s commitment to achieving net-zero emissions by 2050.

Learn more about the award and Agilent’s Certified Pre-Owned Instruments and trade-in and recycling services.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom